The objectives of this open-labeled study were to assess the clinical uroselectivity of alfuzosin in a long-term follow-up study in general practice. A total of 3,228 patients with clinical benign prostatic hyperplasia (BPH) from 812 centers were included in a prospective 3-year open-labeled study and treated with alfuzosin (immediate-release formulation) at the recommended dosage. Symptom score (Boyarsky, modified) and a 20-item BPH-specific health related quality of life (HRQL) score (UrolifeTM BPH QoL 20), which included three questions on sexuality, were self-administered at baseline, 3, 6, 12, 18, 24, 30 and 36 months. Symptom score was significantly reduced by 54% at 3 months and this reduction was maintained up to 36 months; the HRQL score was significantly improved by 45.4% at 12 months and this improvement was also maintained up to 36 months. Alfuzosin was well tolerated: the quantitative and qualitative distribution of adverse events (AEs) was similar to that previously observed in placebo-controlled studies. 4.2% of the patients dropped out due to AEs. This study confirms the long-term safety profile of alfuzosin in general practice and highlights the need to measure HRQL in the context of clinical uroselectivity.

1.
Andersson KE, Lepor H, Wyllie MG: Prostatic α1-adrenoreceptors and uroselectivity. Prostate 1997;30:202–215.
2.
Eri LM, Tveter KJ: α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995;154:923–934.
3.
Jardin A, Bensaddoun H, Delauche-Cavalier MC, Attali P, and the BPH-ALF Group: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991;337:1457–1461.
4.
Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC and the Algebi study group: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997;31:190–198.
5.
Buzelin JM, Delauche-Cavallier MC, Roth S, Geffriaud-Ricouard C, Santoni JP: Clinical uroselectivity: Evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 1997;79:898–906.
6.
Iezzoni LI: Risk adjustment for medical outcome studies; in Grady ML, Schwartz HA (eds): Medical Effectiveness Research Data Methods. Rockville, Agency for Health Care Policy and Research, 1992, pp 83–97.
7.
Guess HA, Chute CG, Garraway WM, Girman CJ, Panser LA, Lee RJ, Jacobsen SJ, McKelvie GB, Oesterling JE, Lieber MM: Similar levels of urological symptoms have similar impact on Scottish and American men – although Scots report less symptoms. J Urol 1993;150:1701–1705.
8.
Mc Connel JD, Barry MJ, Bruskewitz RC, Bueschen AJ, Denton SE Holtgrewe HL, Lange JL, McClennan BL, Mebust WK, Reilly NJ, Roberts RG, Sacks SA, Wasson JH: Benign prostatic hyperplasia: Diagnosis and treatment. Clinical Practice Guideline, No 8. AHCPR Publication No. 94–0582. Rockville, Agency for Health Care Policy and Research, 1994, p 225.
9.
Barry MJ, Fowler FJ, O’Leary M, Bruskewitz RC, Holtgrewe HL, Mebust WK: Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995;33 (suppl):AS145–155.
10.
Mebust WK, Donovan J, Bosch R, Okada K, O’Leary M, Batista J, Boyle P, Villers A, Ackermann R, Hoke G, Lukacs B, Mortensen S: Symptoms evaluation, quality of life and sexuality; in Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, et al (eds): Proceedings of the Third International Consultation on Benign Prostatic Hyperpasia (BPH). Jersey, Scientific Communications International, 1996, pp 257–261.
11.
Lukacs B, Leplege A, Mc Carthy C, Comet D: Construction and validation of a BPH specific health related quality of life scale (with special attention to sexuality), for medical outcome research studies; in Cockett ATK, Khoury S, Aso Y et al (eds): Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, Scientific Communications International, 1994, pp 139–143.
12.
Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D: Quality of life measures in health care. I. Applications and issues in assessment. Br Med J 1992;305:1074–1077.
13.
Boyarsky S, Jones G, Paulson DF, Prout GR: A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genito-Urin Surg 1977;68:29–32.
14.
Comparing treatments: safety, effectiveness, and cost-effectiveness. March 23rd/24th Workshop. FDA, Division of drug marketing, advertising and promotion (DDMAC). Principles for the review of pharmacoeconomic promotion. Script No 2013, April 4th, 1995.
15.
Van Mastrigt R, Rollema HJ: The prognostic value of bladder contractility in transurethral resection of the prostate. J Urol 1992;148:1856–1860.
16.
Lepor H, Nieder A, Feser J, O’Connell C, Dixon C: Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology 1997;49:476–480.
17.
Lukacs B, Leplage A, Thibault P, Jardin A: Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996;48:731–740.
18.
Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Hanley D: Symptom status and quality of life following prostatectomy. J Am Med Assoc 1988;259:3018–3022.
19.
Doll HA, Black NA, Flood AB, McPherson K, Williams GB, Smith JC: Differences in outcome of TURP for benign prostatic hypertrophy between three diagnostic categories. Br J Urol 1993;72:322–330.
20.
Jolleys JV, Donovan JL, Nanchahal K, Peters TJ, Abrams P: Urinary symptoms in the community: How bothersome are they? Br J Urol 1994;74:551–555.
21.
The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 1993;150:1696–1700.
22.
O’Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, Barry M: A brief male sexual function inventory for urology. Urology 1995;46:697–706.
23.
Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995;45:406–413.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.